



Swiss Group for Clinical Cancer Research SAKK

Contact

Swiss Group for Clinical Cancer Research SAKK

Publications (4)

Hitz F, Driessen C, Mey U, Samaras P, Vilei S, Stüdeli S, Rondeau S, Seipel K, Novak U, Silzle T, Besse L, Hess D, Pabst T, Kraus M, Swiss Group for Clinical Cancer Research SAKK. Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). *Blood Cancer J* 2019; 9:70.

Cathomas R, Gillessen Sommer S, Manetsch G, Bernhard J, Mohaupt M, Roggero E, Rauch D, Vilei S, Hayoz S, Kenner H, von Burg P, Elliott T, Rothermundt C, Winterhalder R, Mark M, Crabb S, Swiss Group for Clinical Cancer Research SAKK. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11). *Prostate* 2016; 76:1519-1527.

Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). *Clin Cancer Res* 2012; 18:6049-57.

Ribi K, Stahel R, Ris H, Stupp R, Schmid R, Betticher D, Jörger M, Bodis S, Weder W, Schuller J, Bernhard J, Swiss Group for Clinical Cancer Research SAKK. Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. *Lung cancer (Amsterdam, Netherlands)* 2008; 61:398-404.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch